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ABSTRACT 
 
Both cell mediated and humoral immune responses are required for recovery from Brucella abortus infection. In the 
development of vaccines capable of providing immunity against brucellosis, L7/L12 50S ribosomal protein has been 
demonstrated to be one of the protective immunogens of Brucella abortus. The recombinant Brucella abortus 
L7/L12 ribosomal protein previously produced in the E. coli system was purified by affinity chromatography. The 
DNA vaccine (pVL7/L12) construct was purified in bulk by endotoxin free reagents. The present study was 
designed to evaluate cell mediated immune response and humoral immune response after the intramuscular 
vaccination of mice with DNA vaccine alone (Group 1), recombinant protein alone (Group 2) and DNA vaccine 
followed by recombinant protein boosting (Group 3). The protective efficacy of the said vaccines also evaluated. 
Animals vaccinated with pVL7/L12 (DNA vaccine) alone did not develop L7/L12 specific antibodies at least until 
60 days of vaccination. But recombinant protein induced a strong antibody titer (1:32000) after 60 days of post 
immunization which exhibited a dominance of immunoglobulin IgG2a over IgG1. L7/L12 DNA vaccine elicited a 
T-cell proliferation response and also induced the production of IFN-γ. The lymphocyte proliferation and IFN- γ 
production was significantly higher (P<0.001) in Group 3 than the other groups. Group 3 also induced strong IgG2a 
response. The DNA vaccine followed by protein boosting induced a strong significant level of protection in mice 
against challenge with B. abortus 544. The level of protection in Group 3 was significantly higher than the DNA 
vaccine or recombinant protein alone. Altogether, the data generated in the present study suggested that L7/L12 
DNA vaccine followed by recombinant protein boosting is a good candidate for use in future studies of vaccination 
against brucellosis. 
Keywords: Brucella abortus, DNA vaccine, Immune response, Immunoglobulin, Recombinant protein. 
Introduction 
 
Brucella abortus S19 a smooth, avirulent strain is used 
to vaccinate cattle. Although the S19 vaccine gives 
considerable protection to cattle, it is pathogenic to 
humans and it is not effective in controlling the 
infection of udder, through which milk used for human 
consumption is contaminated with 
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the bacterium. Further, the vaccine strain, cross reacts 
with the serological tests used to diagnose clinically 
infected cases. This is a major drawback in any control 
program. In the given scenario various researchers are 
in the process of developing safe and efficacious 
vaccines against brucellosis. Subunit nucleic acid 
vaccine strategies which negate many of the demerits 
of traditional vaccines give us an opportunity to find a 
suitable solution to control the disease. Many 
immunogenic proteins like Omp 28, Omp 31, Cu-Zn 
SOD, L7/L12 have been tried as recombinant subunit, 
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nucleic acid, synthetic peptide vaccines.L7/L12 50S 
ribosomal protein is a promising candidate because it 
has given good results in mice models. Further, 
Brucellin INRA (sLPS free cytosolic extract from 
rough B. melitensis B115) which is a purified protein 
used in skin test to screen positive cases of brucellosis 
fails to elicit a delayed type hyperimmune (DTH) 
response, when the L7/L12 fraction is removed from 
the purified protein [1]. L7/L12 ribosomal protein 
participates in bacterial protein synthesis by binding 
elongation factor G and TU. Like any other ribosomal 
protein this 12 kDa protein encoded by a 375 bp gene 
is also conserved across many genera of bacteria like 
E. coli, Mycobacteria etc. The exact antigenic motif 
recognized by the host immune system has not yet been 
elucidated. L7/L12 with its helix turn helix DNA 
binding motif makes it a suitable candidate to screen 
for putative T cell epitopes [2]. Any vaccine against 
brucellosis should give a predominantly Th1 mediated 
immune response to clear the infection. IFN-γ 
(interferon) and TNF-α have been implicated as key 
cytokines needed to confer protection against the 
disease. Keeping all this in mind the present work was 
undertaken with the objectives of analyzing cellular 
immune response and humoral immune response 
against L7/L12 recombinant protein and its DNA 
vaccine construct in laboratory animal and to study the 
protective efficacy of recombinant protein and its DNA 
vaccine construct against challenge in laboratory 
animal. 
Material and methods 
Bacterial cultures 
Brucella abortus S19 and Brucella abortus 544 were 
obtained from Brucella Referral Lab., Division of 
Veterinary Public Health, Indian Veterinary Research 
Institute, Izatnagar, India. 
Experimental animals 
Apparently healthy female Swiss albino mice (4 to 6 
weeks age) were obtained from the Laboratory Animal 
Research Section, IVRI, Izatnagar, India. The animals 
were kept under conventional housing condition and 
provided feed and water ad lib. 
Immunoconjugates 
Anti-mouse IgG (H+L) HRPO (horse radish 
peroxidase) conjugate, anti-mouse IgG (Fab) HRPO 
and anti-mouse (IgG1-IgG2a) conjugate were used for 
ELISA and immunoblotting. 
Gamma-Interferon EIA kit 
Sandwich ELISA kit was used to estimate mouse 
Gamma-Interferon level. 
Enzymes 
Restriction endonucleases, Taq DNA polymerase, 
Proteinase-K, RNase-A were used in this study. 
Oligonucleotide primers 
Oligonucleotide primers were designed from published 
sequence of B. abortus. The primers BA1 (Forward) 
and BA2 (Reverse) both had linear sequences at their 5' 
ends. 
BA1  
5'- CGC CGT CGA CAT GGC TGA TCT CGC AAA 
GATC - 3' 
BA2  
 5'- GCC CCT GCA GTC TAG ATT ACT TGA GTT 
CAA CCT TGGC-3' 
Vectors and host cells 
Ins T/A easy vector and DH5α E. coli culture were 
used in this study. 
Plasmid isolation kit 
Endotoxin free plasmid Maxi kit was used for bulk 
DNA vaccine production. 
Molecular weight marker 
Medium range protein molecular weight marker; Pre-
stained molecular weight marker and 100 bp DNA 
ladder were used. 
Recombinant clones 
pPROC L7/L12 for prokaryotic expression and 
pVL7/L12 for DNA vaccine were obtained from IVRI, 
India. 
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Preparation of competent cells 
E. coli stain DH5α was made competent by CaCl2 
method. E. coli strain DH5α was grown for 2 h in 
shaking incubator at 37oC in 10 ml test tube in LB 
broth without ampicillin till the OD of culture 0.2 - 
0.35 was attained. One ml culture was taken in each 1.5 
ml eppendorf tube and pelleted at 6000 rpm for 10 min. 
The pellet was used for subsequent steps. 200 µl of 
0.1M CaCl2 was added in each tube and mixed 
properly. Further it was centrifuged at 6000 rpm for 10 
min at 4oC. The pellet was recovered after discarding 
the supernatant. The pellet was re-suspended in 200 µl 
0.1M CaCl2 and kept in ice for 45 min. Each aliquot of 
cells was used for transformation. 
Transformation of PPROL7/L12 and pVL7/L12 
2 µl of each recombinant plasmid was mixed with 200 
µl of competent cell aliquot and kept in ice for 1 h. 
Positive and negative controls were always kept. Heat 
shock to the cells was given at 42oC for 90 sec and 
cells were then immediately transferred back to ice for 
5 min. About 600 µl of LB medium was added to the 
transformed cells and incubated at 37oC for 45 min. 
The cells were then plated out into the LB agar 
containing ampicillin for pPROL7/L12 and kanamycin 
for pVL7/L12. The plates were incubated at 37oC 
overnight. After incubation the plates were observed 
for presence of colonies and stored at 4oC. 
Screening of recombinant clones 
Few colonies were picked at random and incubated in 3 
ml LB broth containing ampicillin or kanamycin. The 
broths were incubated overnight at 37oC under constant 
shaking. The plasmids were extracted following alkali 
lysis method [3]. 
Screening by PCR 
Plasmid DNA from transformed bacteria was used as 
template for amplification of L7/L12 gene. The PCR 
mixture consisted of 50 ng of template, 30 pM of each 
primers BA1 and BA2, 200 µM of each dNTPs, 5 µl of 
10X PCR buffer and 2.5 units of Taq DNA 
polymerase. The volume of the reaction was made up 
to 50 µl with distilled water. PCR was performed using 
a DNA thermal cycler with the following conditions: 5 
min. at 94oC followed by 30 cycles consisting of 1 min 
at 94oC, 1 min at 50oC, 1 min at 72oC, finally an 
extension of 10 min at 72oC. Around 10 µl of amplified 
product was then analyzed by electrophoresis in a 1.5% 
agarose gel stained with ethidium bromide. 
Screening by restriction endonuclease digestion 
Plasmid isolated from transformed bacteria was 
subjected to double digestion with restriction enzymes. 
Approximately 1.0 µg of plasmid was digested with 1 
unit of restriction endonucleases, BamH1 and Xba1 in 
reaction volume of 20 µl. Digested plasmid was 
electrophoresed on 1.0% agarose gel stained with 
ethidium bromide. 
Sequencing of transformed clones 
After screening by PCR and RE digestion, the 
recombinant clones were to confirm the correct reading 
frame and sequence changes, if any. 
Isolation of plasmid DNA from pVL7/L12 for the 
production of DNA vaccine 
DNA vaccine grade recombinant pVL7/L12 having 
complete gene in right orientation was prepared using 
standard kit following the manufacturer's protocol.  
Quantification of plasmid DNA concentration 
The concentration and purity of DNA was analyzed by 
UV spectrophotometer. The purity of plasmid DNA 
was checked spectrophotometrically by considering the 
ratio of OD260/OD280. 
Production of recombinant protein from pPROC 
L7/L12 in bulk 
Induction of expression 
Overnight culture of the recombinant clone was 
inoculated in 500 ml of LB broth containing ampicillin 
(100 µg/ml) and grown at 37oC with vigorous shaking. 
The culture was induced with IPTG to final 
concentration of 1 mM when the OD at 600 nm 
reached 0.5. After 5 h the culture was washed thrice 
with PBS and re-suspended in 25 ml PBS. Then the 
culture was stored at -20oC till further use. 
SDS-PAGE analysis of the protein 
SDS-PAGE analysis was carried out as described by 
Laemmli [4] in a vertical mini-gel electrophoresis 
apparatus using 15% resolving gel having a stacking 
gel of 5% concentration. Electrophoresis was carried 
out at a constant current of 18 mA, until the tracking 
dye reached the bottom of the gel. The gel was taken 
out from the plates and stained with 0.25% (W/V) 
Coomassie brilliant blue R-250 prepared in methanol, 
glacial acetic acid and water (45:10:45) and destained 
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with destaining solution (20 parts methanol : 10 parts 
glacial acetic acid and 70 parts distilled water). 
Purification of recombinant L7/L12 protein 
Polyhistidine tagged fusion protein was purified under 
denaturing conditions by metal chelate affinity 
chromatography with certain modifications introduced 
in the purification parameter.50 µl of induced culture 
was re-suspended in 4 ml of lysis buffer (buffer B) 
containing imidazole (20 mM), 1M NaCl, glycerol 
(20%) and Tritonx 100 (25%). It was held at room 
temperature for 1 h with intermittent mixing. The cell 
debris was removed by centrifugation at 10,000 rpm 
for 20 min. The supernatant was incubated with 1 ml of 
Ni-NTA resin for 40 min and packed into column. 
Thereafter column was washed thoroughly with wash 
buffer (buffer C). The fusion protein was eluted in 0.5 
ml x 4X with the elution buffer (buffer E). Five elutes 
were collected. Elutes were checked by SDS-PAGE as 
described earlier. Elutes were dialyzed against PBS to 
remove urea. 
Estimation of concentration of recombinant protein 
Concentration of recombinant protein, L7/L12 was 
estimated by protein-estimation kit according to the 
protocol originally described by Lowry et al. [5] taking 
BSA as a standard. 
Preparation of B. abortus 544 for challenge study 
and B. abortus S19 for vaccination 
Brucella abortus 544 and B. abortus S19 were 
subcultured separately on Tryptose phosphate agar on 
Tubes as slant culture and incubated at 37oC for 48 h. 
B. abortus 544 culture was incubated under 5% CO2 
tension. The growths were harvested with tryptose 
phosphate broth by gentle shaking. 
Viable count was determined as per method described 
by Alton et al. [6] with some modifications. Tryptose 
phosphate agar was used for the enumeration of the 
organisms. Serial 10-fold dilution of the suspension 
was made up to 10-10 in tryptose phosphate broth. From 
the dilution 10-1 to 10-10, 10 µl was taken and plating 
was done on tryptose phosphate agar using three 
replica for each dilution. The plates were incubated at 
37oC for 48-72 h. For B. abortus 544 plates were 
incubated under 5% CO2 tension. Plates showing 30-
300 cfu were selected for colony count. The mean of 
all the plates was multiplied by dilution factor. This 
was taken on the number of viable Brucella in the 
suspension. 
Preparation of sonicated antigen from Brucella 
Sonicated antigen was prepared following the method 
described by Zoha and Carmichael [7] with slight 
modification. The antigen was prepared from live 
Brucella abortus S19. The organisms were first heat 
killed at 65oC for 2 h, and then it as harvested in PBS. 
After centrifugation at 10,000 g for 20 min, cell 
sediment was washed again in PBS. Equal volume of 
sediment and PBS was mixed and sonicated for 30 
cycles for 1 min each at amplitude of 30. The sonicated 
cell suspension was centrifuged at 15,000 g for 1 h. 
The supernatant was taken as sonicated antigen extract. 
Concentration of this sonicated antigen was estimated 
by protein-estimation kit as originally described by 
Lowry et al. [5]. 
Experimental vaccination trial in mice 
A total of 75 number of six week old female Swiss 
albino mice were housed in cage and fed ad lib. Mice 
were allowed to acclimatize for 1 week before 
vaccination. Five vaccine groups of 15 mice each were 
immunized by deep intramuscular route with various 
preparations as given below: 
Group 1 
50 µg (a total volume of 300 µl in PBS) of L7/L12 
DNA vaccine (PVL7/L12) was injected to each mouse. 
Two boosters were given with same concentration of 
DNA vaccine on day 15 and day 30. 
Group 2 
30 µg (a total volume of 150 µl in PBS) of recombinant 
L7/L12 protein was emulsified with 150 µl of Freund's 
incomplete adjuvant was injected to each mouse. 2 
Booster were given with same concentration of protein 
on day 15 and day 30. 
Group 3 
50 µg (a total volume of 300 µl in PBS) of pVL7/L12 
was injected to each mice. Two boosters were given 
with 30 µg of recombinant L7/L12 protein to each mice 
at day 15 and day 30. 
Group 4 
50 µg (a total volume of 300 µl in PBS) of pVax vector 
was injected to each mice as vector control. Boostering 
were done by same concentration of vector on day 15 
and day 30. 
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Group 5 
300 µl of PBS to each mouse. 
Study on humoral immune response 
Serum samples were collected from the mice on day 0, 
day 7, day 14, day 30, day 45 and day 60. 
Detection of antibody by ELISA from collected 
serum samples 
The presence of serum immunoglobulin G (IgG), IgG1 
and IgG2a isotypes with specificity to L7/L12 was 
determined by indirect ELISA. The purified 
recombinant L7/L12 was diluted to 500 ng/ml in 
carbonate buffer (pH 9.6) and used to coat the wells of 
polystyrene plates (100µl/well). The plates were 
incubated at 4oC overnight. Next day plates were 
washed thrice with PBS-T (phosphate-buffered saline 
containing 0.1% Tween-20). Blocking was done with 
1% BSA in PBST and incubated for 1 h at 37oC. Plates 
were washed thrice with PBS-T. Sera samples 
collected at different days along with negative control 
in the dilution of 1:200 were put in 100 µl quantity per 
wall. The plates were incubated at 37oC for 60 min and 
washed thrice as before. Anti-mouse conjugates were 
added (100 µl/well) at an appropriate dilution. The 
plates were again incubated at 37oC for 60 min and 
washed thrice as before. Finally 100 µl of freshly 
prepared substrate solution was added to each well. 
The plates were incubated for 15 min in the dark and 
the reaction was stopped by addition of 100 µl of 0.18 
M H2SO4 per well. Absorbance was measured at 492 
nm. 
Western blot analysis 
Serum samples of different days in different dilutions 
were assayed by Western blot. Western blotting was 
carried out according to Towbin et al. [8] with some 
modifications. Purified r-L7/L12 fusion protein, 
sonicated Brucella antigen and prestained marker were 
loaded on 15% SDS-PAGE and electro-blotted on to 
nitrocellulse paper (NCP) at 2 mAmp/cm2 constant 
current for an hour, the transfer was carried out in 
semidry electro blot apparatus. After the transfer the 
nitrocellulose paper was blocked by 5% skim milk 
powder for overnight. After completion of blocking, 
the NCP was washed thoroughly followed by cutting. 
Strips were incubated with appropriate dilutions of 
different serum at 37oC for 1 h. After the reaction 
primary antibody, NCP was washed three times with 
PBS-T and incubated with antimouse IgG-HRPO 
conjugate for 1 h. Color development was carried out 
with substrate DAB/NiCl2/H2O2 visualization solution. 
After the optimum color was developed, the NCP was 
washed with excess water to stop the reaction. 
Detection of cell mediated immune response 
Splenocyte cultures and lymphocyte proliferation assay 
[9]. Mice were sacrificed at various time intervals of 
post immunization for collection of splenocytes to 
detect the in vitro CMI response. After one week, 3 
weeks and 6 weeks of post immunization mice were 
sacrificed and their spleens were removed under 
aseptic conditions. 
Several perfusions were made in spleen by using 1 ml 
tuberculin syringe having fine needle. Then the cells 
were slowly washed out by PBS-D solution. About 3 
ml of washed cells was aseptically layered over 3 ml 
Histopaque in 15 ml plastic centrifuge tubes. The tubes 
were centrifuged at 1400 rpm for 40 min at 4oC. The 
interface ring rich in mononuclear cells were collected 
carefully and washed twice in sterile PBS-D at 1200 
rpm for 10 min each time. The cells were then re-
suspended in RPMI 1640 and medium washed again. 
Finally the cells were suspended in RPMI 1640. 
Viability of cells was ascertained by trypan blue dye 
exclusion method and cell concentration was adjusted 
to achieve a cell count of 4 x 106 cells/ml. Splenocytes 
were cultured at 37oC with 5% CO2 in a 96-well flat-
bottom plate at a concentration of 4 x 105 viable 
cells/well in the presence of 0.4 µg sonicated B. 
abortus S19 proteins, 0.08 µg of purified L7/L12, 0.25 
µg of Concavalin A per well, or no additives (non-
stimulated control) according to Onate et al. [10]. 
Phenol red free RPMI-1640 medium supplemented 
with 2 mM L glutamine, 10% heat inactivated fetal calf 
serum and 50 µl of penicillin-streptomycin was used 
for culturing the splenocytes. After 96 h, 20 µl of MTT 
solution (5 mg/ml in PBS) was added to each well and 
further incubated for 4 hrs and the plates were then 
centrifuged at 1500 rpm for 10 min. 100 µl of culture 
supernatant was discarded from each well. Finally, 150 
µl of dimethylsulfoxide (DMSO) was added to each 
well and mixed thoroughly avoiding any foam 
formation in order to dissolve formazan crystals. The 
intensity of colour development was measured by 
taking absorbance (OD) at wavelength of 570 nm with 
the reference wavelength of 630 nm in microplate 
reader. 
Stimulation index (SI) was calculated using the 
following formula                                               
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OD of stimulated culture =                
                                Mean SI (MTT) 
                 Mean OD of non-stimulated culture 
 
Detection of Gamma-Interferon level in immunized 
mice 
For detection of IFN-γ, culture supernatants of spleen 
cells were collected after 48 h of antigen stimulation 
and tested for the presence of IFN-γ by antigen capture 
ELISA using Opt EIA Set Mouse IFN-γ. All assays 
were performed in triplicate. 
The concentration of IFN-γ in the culture supernatants 
was calculated for each experimental group using a 
linear-regression equation obtained from the 
absorbance values of the standards. 
Protection experiments 
A total of 72 no. six weeks old female Swiss albino 
mice were housed into six groups. Mice were allowed 
to acclimatize for 1 week before vaccination. 12 mice 
were taken for each group as given below. 
Immunization with different antigens 
Group 1: DNA vaccine (pVL7/L12) 
Group 2: Recombinant protein vaccine (pPROL7/L12) 
Group 3: DNA vaccine followed by protein boosting 
Group 4: B. abortus S19 vaccine (positive control 
group) 
Group 5: PBS (control group) 
Group 6: PVax1 vector (Vector control group) 
Vaccination schedule, doses and routes of 
immunization: 
DNA vaccine and pVax1 vector were given through 
intramuscular route at dose rate of 50 µg per animal. 
Two boosters immunization were performed at day 15 
and day 30 of primary immunization. Recombinant 
protein vaccine was given through intramuscular route 
at a dose of 30 µg per animal. Two boosters 
immunization were performed at day 15 and day 30 of 
primary immunization. One group of animals was 
given DNA vaccine and two boosters immunization 
were performed with recombinant protein vaccine. B. 
abortus S19 was given through intra-peritoneal route at 
dose rate 5 x 104 cfu (colony forming unit) per animal. 
No booster immunization was performed in this group. 
PBS control group was received only phosphate buffer 
saline (0.2 ml) by intramuscular route. 
Challenge of animals by pathogenic Brucella 
Thirty days after booster immunization all the mice 
were challenged with virulent Brucella abortus spp. 
Animals were challenged with 5 x 104 live cells of B. 
abortus 544 strain by intraperitoneal route. Four weeks 
after challenge, the mice were sacrificed for splenic 
clearance assay. Spleens were removed from the mice 
aseptically, homogenized in 2 ml of TPB (Tryptose 
phosphate broth). 10-fold serial dilutions were made in 
TPB and plated in triplicate. B. abortus 544 colonies 
were counted after 3 days of incubation at 37oC with 5-
10% CO2. 
Statistical analyses 
The data for lymphocyte proliferation, detection of 
IFN-γ and splenic clearance were analyzed by one way 
analysis of variance and mean effect by using Duncan 
multiple range test [11].s L7/L12 gene. 
 
Results 
Screening of recombinant clones (pPROL7/L12 and 
pVL7/L12) 
Screening by PCR 
Plasmid DNA from transformed bacteria was used as a 
template for PCR reaction and BA1 and BA2 used as 
forward and reverse primers. A single band of 375 bp 
was found in agarose gel electrophoresis of the 
amplified product. It was same as desired size of the 
gene. 
Screening by Restriction endonuclease digestion 
Plasmid DNA isolated from transformed bacteria was 
subjected to double digestion by BamH1 and Xba1. On 
agarose gel electrophoresis of the digested product the 
band size was same as PCR product. 
Sequencing of transformed clones 
The recombinant clones were sequenced. Sequences of 
both the clones were same and correct reading frame. 
The sequences were analyzed in PROTEAN 
programme of laser gene software. The predicted 
protein structure and amino acid sequence was same as 
desired L7/L12 protein. 
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Isolation of vaccine grade endotoxin free plasmid 
DNA and quantification 
Plasmid DNA was isolated in bulk by using standard 
kit. Plasmid was checked in agarose gel 
electrophoresis. Further, the plasmid DNA was also 
checked for purity and concentration 
spectrophotometrically by recording OD at 260 and 
280 nm. The purified DNA had the yield of around 400 
µg from 250 ml culture. The ratio of OD260/OD280 
was 1.8, indicating DNA preparations to be pure and 
free from RNA and protein contaminations. 
Production and quantification of recombinant 
protein from pPRO: L7/L12 in bulk 
The culture was induced with IPTG when OD at 600 
nm reached 0.5. After 5 h induction the culture was 
pelleted and washed with PBS. Then the culture was 
lysed by Buffer ‘B’ (pH 8.0). The lysate was checked 
in SDS-PAGE. A distinct band was observed and that 
band was absent in non-induced culture. After 
checking polyhistidine tagged fusion protein was 
purified under denaturing conditions by metal chelated 
affinity chromatography (as per manufacturer’s 
protocol), with some modification introduced in the 
purification parameter. Different elutes were checked 
in SDS-PAGE. No non-specific band was found in the 
purified protein when analyzed in SDS-PAGE. Pure 
distinct single band at 22 kDa position was observed. 
Then elutes were subjected to dialysis against PBS. 
Then the concentration of the purified dialyzed protein 
was estimated by protein-estimation kit. The 
concentration of the protein was 0.5 µg/µl). The 
purified protein had the yield of around 4.5 mg from 
500 ml of culture. Hence the recombinant clone had 
given high level of expression. 
Humoral immune response studies in mice 
Detection of antibody by ELISA from collected serum 
samples 
The presence of serum immunoglobulin G (IgG), IgG1, 
and IgG2a isotypes with specificity to recombinant 
L7/L12 protein was determined by indirect ELISA. 
The level of anti L7/L12 antibodies were measured in 
pooled serum from the DNA vaccine alone (Group 1), 
recombinant protein alone (Group 2), DNA vaccine 
followed by protein boosting (Group 3), Vector control 
(Group 4) and PBS control (Group 5). Animals 
inoculated with DNA vaccine showed very low levels 
of anti L7/L12 antibody. Recombinant protein vaccine 
group showed a sharp increase in IgG level at 21 days 
of immunization and it was increased up to 45 days 
immunization and maintained up to 60 days. But there 
was a sharp increase in serum IgG level after 30 days 
of immunization in case of Group 3 and it was 
maintained at least up to 60 days of immunization. 
None of the animals inoculated with pVAX vector and 
PBS control showed anti-L7/L12 antibodies. Serum of 
Groups 2 and 3 were pre-dominantly IgG2a. High level 
of IgG2a was detected after 21 days of immunization in 
case of Group 2 and 30 days of post immunization in 
case of Group 3. But after 45 days of immunization the 
level of IgG2a was higher in Group 3 than Group 2 and 
it was maintained at 60 days of post immunization. A 
rise in serum IgG1 level was observed at 21 days in 
case of Group 2 but then it declined gradually. But in 
case of Group 3 the IgG1 level was very less. 
In a repeat experiment the titration of the sera samples 
of recombinant protein vaccinated mice were done in 
ELISA. Brucella positive serum also has been titrated. 
After 30 days of post immunization the titer was 
1:32000 and maintained up to 60 days of post 
immunization. But the titer declined at 90 days post-
immunization. Only 1:16000 serum titer was detected 
after 90 days of immunization. Brucella positive serum 
also showed high titer (1:32000). 
Western blot analysis 
In western blot analysis recombinant L7/L12 protein 
and Brucella sonicated antigen reacted to Group 2 
serum. After 14 days of immunization of Group 2 and 
after 30 days of immunization in case of Group 3 
serum in a dilution of 1:1000 strongly reacted to 
Brucella antigen. Brucella positive serum in a dilution 
of 1:1000 strongly reacted to L7/L12 recombinant 
protein. Serum collected from Group 2 at 90 days of 
post immunization strongly reacted to L7/L12 
recombinant protein in 1:1000 dilution. None of the 
sera collected from DNA vaccine alone (Group 1) 
reacted in western blot. Also serum from the vector 
(pVax) control and from the PBS control group did not 
give any reaction in western blot. 
Detection of cell mediated immune response 
Lymphocyte proliferation assay 
Lymphocyte proliferation assay by MTT was 
conducted at 3 different time intervals after 
immunization. After first week, third week and sixth 
week of post immunization, mice were sacrificed and 
their spleens were removed under aseptic conditions. 
Splenocytes were separated by the method described 
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earlier. Splenocytes were cultured with different 
stimulus and stimulation indices were measured by 
MTT colorometric assay. Splenocytes from none of the 
mice immunized with DNA vaccine (Group 1), 
recombinant protein (Group 2) had an increased 
proliferative response to recombinant L7/L12 and 
sonicated antigen after 1 week of immunization. The 
splenocytes from the three experimental groups and 
two control groups had very similar proliferative 
response to the mitogen ConA throughout the study. 
After 3rd week of immunization splenocytes from 
Group 1, Groups 2 and 3 showed significantly higher 
proliferation (P<0.001) than the control groups. When 
stimulated by recombinant protein antigen, the Groups 
1 and 2 showed stimulation indices 1.256±0.0197 and 
1.147±0.0165 respectively. Splenocytes when 
stimulated by sonicated antigen the stimulation indices 
of Groups 1 and 2 were 1.230±0.0197 and 
1.194±0.0162 respectively. But in comparison to others 
the Group 3 showed highest stimulation index 
(1.277±0.0170) when stimulated with Brucella 
sonicated antigen. It was significantly higher (P<0.001) 
than the control groups. The control group did not 
show increased stimulation indices in any case, either 
stimulated by recombinant protein or Brucella 
sonicated antigen. Hence, Group 3 (DNA vaccine 
followed by protein boosting) showed highest 
proliferative response and Group 2 (Recombinant 
protein group showed least increased proliferative 
response when they are stimulated by sonicated 
Brucella antigen. Proliferation level increased 
significantly in Groups 1 and 3 after 6th week of 
immunization. Group 3 showed highest proliferation. 
Group 3 splenocytes when stimulated by sonicated 
antigen the mean value of stimulation indices was 
1.609±0.0129. The value was significantly higher 
(P<0.001) than the control group. The mean 
stimulation index of Group 3 splenocytes in case of 
recombinant protein stimulation was 1.524±0.0179. 
That was also significantly higher (P<0.001) than that 
of control value. When Groups 1 and 2 splenocytes 
were stimulated by sonicated antigen the mean values 
of stimulation indices were 1.362±0.0283 and 
1.270±0.0169 respectively. In case of recombinant 
protein stimulation the mean values were 1.340±0.0306 
and 1.215±0.0192 respectively. The highest 
proliferation was found in Group 3. Group 2 showed 
least increased proliferation in comparison to Groups 1 
and 3. Significant difference also found in between 
Groups 1 and 3. Hence DNA vaccine followed by 
protein boosting gave best proliferative response in 
comparison to DNA vaccine alone or recombinant 
protein alone. 
Interferon-Gamma assay 
IFN-γ assay by Opt EIA kit was conducted at 3 
different time intervals after immunization. It was done 
simultaneously with lymphocyte proliferation assay. 
Splenocytes were cultured with different stimulus and 
then supernatants were collected and assayed by 
antigen capture ELISA. The concentration of IFN-γ in 
the culture supernatants was calculated for each 
experimental group using a linear regression equation 
obtained from the absorbance values of the standards. 
DNA vaccine (Group 1) and Recombinant protein 
(Group 2) did not show increased level of IFN-γ 
concentration after 1 week of immunization. After 3rd 
week of immunization, the entire vaccinated group 
showed increased level of IFN-γ. In comparison to 
other the Group 3 showed highest level of IFN-γ when 
stimulated with sonicated antigen. IFN-γ level was 
significantly higher (P<0.001) in Groups 1 and 3 after 
6th week of immunization. Group 3 showed highest 
level of IFN-γ when stimulated by sonicated antigen. 
None of the control mice showed increased level of 
IFN-γ after stimulation. 
Efficacy of vaccine in generating protective 
immunity against B. abortus 544 
Protection experiments were carried out by challenging 
vaccinated and control mice by intraperitoneal 
injection of virulent B. abortus 544 and the level of 
infection was evaluated by determining the CFU in 
their spleens. The results indicate that Group 1, Groups 
2 and 3 showed significantly higher (P<0.05) 
protection compared to the non-immunized control 
group. To compare the extent to which mice could be 
protected, Group 1 induced 1.204 log protection, 
Group 2 induced 1.289 log protection, Group 3 induced 
1.427 log protection and the S19 strain induced 2.662 
log protection. No significant difference was found 
between groups injected with pVax vector and PBS. 
DNA vaccine followed by protein boosting showed 
higher degree of protection against Brucella infection 
in comparison to DNA vaccine and recombinant 
protein vaccine alone. 
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Table 1: Mean OD values of L7/L12 specific IgG response of different experimental groups of mice in ELISA 
S.No. Experimental 
groups 
0  
day 
7  
day 
14 day 21 day 30 day 45 day 60 day 
1. DNA vaccine 0.254 0.243 0.276 0.319 0.304 0.439 0.424 
2. Recombinant 
protein 
0.235 0.602 0.672 1.652 2.187 2.540 2.469 
3. DNA vaccine 
followed by 
protein 
boostering 
0.206 0.255 0.247 0.88 2.548 3.190 3.304 
4. Vector (pVax 
control) 
0.178 0.219 0.220 0.295 0.417 0.381 0.337 
5. PBS control 0.193 0.205 0.237 0.251 0.280 0.264 0.259 
Each value represents the OD of pooled serum samples of five mice under same group 
 
Table 2:Mean OD vales of L7/L12 specific immunoglobulin isotype (IgG2a) antibody response of mice 
vaccinated with recombinant L7/L12 protein alone and DNA vaccine followed by protein boosting group by 
ELISA 
S.No. Group 
No. 
Experimental 
groups 
0 day 7 day 14 day 21 day 30 day 45 day 60 day 
1. 2 Recombinant 
protein 
0.144 0.415 0.473 1.279 1.382 1.856 1.861 
2.. 3 DNA vaccine 
followed by 
protein 
boostering 
0.189 0.220 0.239 0.756 1.250 3.251 3.268 
 
Table 3: Mean OD values of L7/L12 specific IgG1 antibody response of mice vaccinated with recombinant 
L7/L12 protein alone and DNA vaccine followed by protein boosting group by ELISA 
S.No. Group 
No. 
Experimental 
groups 
0 day 7 day 14 day 21 day 30 day 45 day 60 day 
1. 2 Recombinant 
protein 
0.248 0.453 0.635 1.203 1.165 0.921 1.865 
2.. 3 DNA vaccine 
followed by 
protein 
boostering 
0.178 0.243 0.204 0.458 0.621 0.542 0.460 
 
Table 4: Mean OD values of L7/L12 specific IgG response of different dilution in different days interval of 
post immunization with recombinant L7/L12 protein and Brucella infected serum 
Dilution Brucella 
positive 
14 day 21 day 30 day 45 day 60 day 90 day 0 day 
1000 1.3895 0.3285 0.775 1.5415 0.639 1.7145 1.5785 0.089 
2000 1.096 0.181 0.4065 1.172 1.208 1.4565 0.998 0.07 
4000 0.7395 0.096 0.2175 0.8395 0.855 1.158 0.6725 0.047 
8000 0.4335 0.0855 0.122 0.521 0.519 0.7945 0.40 0.05 
16000 0.25 0.066 0.076 0.284 0.301 0.4925 0.2325 0.046 
32000 0.1445 0.0545 0.057 0.16 0.172 0.296 0.125 0.0525 
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Table 5:Detection of titer at different day intervals of post immunization with recombinant L7/L12 protein 
and Brucella infected serum 
Days Titer 
Brucella positive 32000 
14 days 2000 
21 days 8000 
30 days 32000 
45 days 32000 
60 days 32000 
90 days 16000 
0 day <1000 
 
Table 6: Antigenic specific blastogenic response of splenocytes of mice at 1 week of post vaccination as 
measured by MTT colorimetric assay 
Experimental groups Number of animals Stimulation index±SE 
Recombinant protein 
antigen 
Sonicated antigen 
DNA vaccine 3 1.07±0.0125a 1.058±0.0130a 
Recombinant protein 3 0.955±0.0098a 1.039±0.0122a 
DNA vaccine followed 
by protein boostering 
3 1.030±0.0106a 0.932±0.00216a 
Vector (pVax control) 3 0.961±0.0272a 0.998±0.0085a 
PBS control 3 0.973±0.0201a 0.856±0.0104 
aDenotes no significant different between the groups 
 
Table 7:Lymphocyte proliferative response by MTT at 3rd week of post-immunization in mice 
Experimental groups Number of animals Stimulation index±SE 
Recombinant protein 
antigen 
Sonicated antigen 
DNA vaccine 4 1.256±0.0197a 1.230±0.0197ab 
Recombinant protein 4 1.147±0.0165b 1.194±0.0162b 
DNA vaccine followed 
by protein boostering 
4 1.242±0.0164a 1.277±0.0170a 
Vector (pVax control) 4 1.089±0.0175c 1.020±0.0197c 
PBS control 4 0.893±0.0185d 1.018±0.0167c 
a,b,c,dMeans bearing different superscripts in a column differ significantly (P<0.001) 
Table 8: Lymphocyte proliferative response by MTT at 6th week of post-immunization in mice 
Experimental groups Number of animals Stimulation index±SE 
Recombinant protein 
antigen 
Sonicated antigen 
DNA vaccine 4 1.340±0.0306b 1.362±0.0283b 
Recombinant protein 4 1.215±0.0192c 1.270±0.0169c 
DNA vaccine followed 
by protein boostering 
4 1.524±0.0179a 1.609±0.0129a 
Vector (pVax control) 4 1.013±0.013d 1.058±0.0165d 
PBS control 4 1.044±0.0314d 1.036±0.0350d 
a,b,c,dMeans bearing different superscripts in a column differ significantly (P<0.001) 
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Table 9: IFN-γ levels measured by sandwich ELISA at 1 week of post-immunization in mice 
Experimental groups Number of animals Concentration of IFN-γ (ng/ml)±SE 
Stimulated by 
recombinant L7/L12 
protein 
Stimulated by 
sonicated Brucella 
protein 
DNA vaccine 3 0.318±0.0514a 0.302±0.0730b 
Recombinant protein 3 0.290±0.0322a 0.317±0.0477c 
DNA vaccine followed 
by protein boostering 
3 0.311±0.0656a 0.325±0.080a 
Vector (pVax control) 3 0.294±0.0246a 0.285±0.033d 
PBS control 3 0.288±0.0315a 0.291±0.048d 
aNo significant different between the groups 
Table 10:IFN-γ levels measured by sandwich ELISA at 3 weeks of post immunization in mice 
Experimental groups Number of animals Concentration of IFN-γ (ng/ml)±SE 
Stimulated by 
recombinant L7/L12 
protein 
Stimulated by 
recombinant L7/L12 
protein 
DNA vaccine 4 1.872±0.121a 2.196±0.246b 
Recombinant protein 4 1.256±0.0347b 1.488±0.0406b 
DNA vaccine followed 
by protein boostering 
4 1.760±0.260a 2.320±0.177a 
Vector (pVax control) 4 0.302±0.0164c 0.290±0.0248c 
PBS control 4 0.289±0.0217c 0.311±0.0309 
a,b,c,dMeans bearing different superscripts in a column differ significantly (P<0.001) 
Table 11: IFN-γ levels measured by sandwich ELISA at 6 weeks of post-immunization in mice 
Experimental groups Number of animals Concentration of IFN-γ (ng/ml)±SE 
Stimulated by 
recombinant L7/L12 
protein 
Stimulated by 
recombinant L7/L12 
protein 
DNA vaccine 4 2.85±0.178a 3.165±0.192b 
Recombinant protein 4 1.547±0.135b 1.79±0.141c 
DNA vaccine followed 
by protein boostering 
4 3.217±0.191a 4.66±0.287a 
Vector (pVax control) 4 0.310±0.0583c 0.323±0.0626d 
PBS control 4 0.296±0.0335c 0.308±0.0219d 
a,b,c,dMeans bearing different superscripts in a column differ significantly (P<0.001) 
Table 12:Protection conferred against Brucella abortus 544 in mice after immunization with recombinant 
protein and DNA vaccine after 30 days post challenge 
Vaccine Log10 CFU of B. abortus 544 in 
spleen (Mean±SE) 
Log10 units of protection 
DNA vaccine 4.228±0.165 1.204b 
Recombinant protein 4.143±0.058 1.289c 
DNA vaccine followed by 
protein boostering 
4.005±0.207 1.427a 
Vector (pVax control) 2.81±0.471 2.622d 
PBS control 5.432±0.123 - 
pVax 5.344±0.208 0.088 
a,b,c,dMeans bearing different superscripts in a column differ significantly (P<0.05) as compared to control values  
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Discussion 
In the present study protection experiments were 
carried out by challenging vaccinated and control mice 
by intra-peritoneal infection of virulent B. abortus S44, 
and the level of infection was evaluated by determining 
the cfu in their spleens. Mice which were immunized 
with rL7/L12 protein induced 1.289 log protection and 
mice vaccinated with S19, induced 2.622 log 
protection. These results were significantly higher 
(P<0.05) than that of vector control and PBS control. 
Among the recombinant antigens that have been tested 
previously so far, HtrA, GroEL, GroES, UvrA and 
YajC induced cellular and humoral immune responses 
in mice, but only the L7/L12 [12,13] elicited some 
level of protection. So there is a agreement between the 
present work and previous studies. E. coli expressing 
the Cu/Zn SOD also conferred a significant level of 
protection (1.77 log units) [13]. Onate et al. [13] also 
reported that the complete Cu/Zn SOD protein could 
induce a protective immune response in mice. But that 
report was contradictory with the results of Tabatabai 
and Pugh [14] who were unable to induce a protective 
immune response in mice using a combination of 
adjuvants and purified recombinant Cu/Zn SOD 
protein as the vaccine antigen, although some level of 
protection was induced with synthetic peptides of the 
protein and adjuvant.DNA vaccination is a relatively 
novel and powerful method of immunization DNA 
vaccination is a powerful method of immunization that 
induces strong cellular immune responses to a wide 
range of pathogens in many animal models for 
different diseases [15]. In the present study DNA 
vaccination induced 1.204 log protection that was 
lower than that of recombinant protein vaccination 
alone and DNA vaccine followed by protein boosting 
but significantly higher (P<0.001) than that of pVax 
vector control and PBS control. Based on the results 
obtained with DNA vaccine against other pathogenic 
intracellular bacteria, many studies were being 
developed using immunizations that code for proteins 
with immunogenic properties for brucellosis. The 
results of those experiments showed that those vaccines 
induced an immune response and some level of 
protection against challenge with pathogenic strain of 
B. abortus [10,16]. Previous reports demonstrated that 
intramuscular inoculation with a DNA vaccine that 
coded for L7/L12 elicited a strong protective response 
[17]. As described previously, viable B. abortus RB51 
conferred over 2 log units of protection [14]. Munoz-
Montesino et al. [18] concluded that intra-spleen 
delivery of a DNA vaccine containing the Cu/Zn SOD 
was able to generate a protective immunity but 
intramuscular administration of that vaccine in the 
same doses and under the same conditions as the 
subcutaneous inoculation did not lead to a significant 
protective immune response [10]. Those results 
demonstrated a higher efficacy of the subcutaneous 
route of administration and they were in agreement 
with the results obtained by Cano et al. [19] and Maloy 
et al. [20]. 
 Conclusion 
In the present study, the lower antibody response after 
DNA vaccine immunization could be due to the low 
level of antigen processing by exogenous pathway. 
Group 2 and Group 3 showed high level of antibody 
response up to 60 days of post immunization. Increased 
level of IgG2a over IgG1 indicated that the 
experimental vaccine given a Th1 type of response. 
Maximum splenocyte proliferative response and IFN-γ 
level has been observed in case of DNA vaccine 
followed by protein boosting. Recombinant protein 
potentiated the effect of L7/L12 DNA vaccine to direct 
the immune response towards Th1 type. DNA vaccine 
followed by protein boosting gave higher level of 
protection than DNA or protein alone. To overcome 
silencing of the genes, in order to generate DNA 
vaccine that expresses for extended periods of time, 
protein boosting is necessary. S19 vaccination has 
given highest protection level than that of other 
vaccinated groups in the present study. 
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